Restylane Lyft has been approved for cheek augmentation and correction of age-related midface contour deficiencies in people more than 21 years of age, the manufacturer, Galderma announced on July 2.
Restylane Lyft, an injectable hyaluronic acid gel, contains lidocaine. It is already approved for mid- to deep-dermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, and for submucosal implantation for lip augmentation in patients 21 years and older, according to the prescribing information.
Approval of Restylane Lyft was based on a study of 200 patients; results included improvements “in the fullness in the right and left midface areas (combined) at 2 months” in almost 90% of the patients, according to a statement from the manufacturer.
The most common adverse events included tenderness, redness, bruising, swelling, and itching, most of which resolved within 2 weeks, the release said.
Contraindications to Restylane Lyft included severe allergies (a history of anaphylaxis or the history or presence of multiple severe allergies) and bleeding disorders.
Restylane Lyft was previously marketed as Perlane-L, according to Galderma.